{
    "id": "64163660690f196b5100001d",
    "question": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To determine whether deflazacort is more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy, we need to consider the pharmacological properties and clinical outcomes of both medications.\\n\\nDeflazacort is a synthetic corticosteroid with a longer duration of action compared to prednisone/prednisolone, which allows for once-daily dosing. This can improve patient compliance and reduce the risk of steroid-related side effects.\\n\\nIn the context of Duchenne muscular dystrophy, prednisone/prednisolone is the standard treatment to reduce muscle damage and delay disease progression. However, long-term use of prednisone/prednisolone can have significant side effects, including osteoporosis, cataracts, and glaucoma.\\n\\nDeflazacort has been shown to have a more favorable side effect profile compared to prednisone/prednisolone, with fewer reports of osteoporosis and cataracts. Additionally, deflazacort has been shown to be more effective in reducing the rate of disease progression in patients with Duchenne muscular dystrophy.\\n\\nTherefore, based on its pharmacological properties and clinical outcomes, deflazacort appears to be more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy.\\n\\n\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 13.336085319519043
}